Dr Reddy's Semaglutide Injection Wins Canada Approval

Dr. Reddy's Laboratories has secured a key regulatory win as its semaglutide injection receives approval from Health Canada, marking a major step in the global rollout of lower-cost alternatives to blockbuster diabetes and weight-loss drugs.

The semaglutide injection—the active ingredient used in widely known treatments like Ozempic—will now be available in the Canadian market, making it one of the first generic versions approved in a developed economy.

This approval positions Canada as an early adopter among major markets to allow generic competition in the fast-growing GLP-1 segment. These drugs are widely prescribed for managing type 2 diabetes and are increasingly used for weight management, driving massive global demand. With branded versions often priced at a premium, the entry of a generic semaglutide injection is expected to improve accessibility for patients.

Also Read: New Dynamics of Drug Distribution, Free Medicine Schemes in India

Neeraj Sharma, CEO & MD, OneSource Speciality Pharma Limited, speaking on the development, said: We are pleased to announce that our partner Dr. Reddy's has received approval from Health Canada for Semaglutide Injection, a generic version of Ozempic. This approval further strengthens our collaboration, combining Dr. Reddy's expertise in peptide development with OneSource's CDMO capabilities.

For Dr. Reddy’s, the development opens a new international revenue stream and strengthens its footprint in the high-growth diabetes care segment. The company has been actively expanding its specialty and complex generics portfolio, and this approval aligns with its broader strategy to compete in regulated markets.

The move could also intensify competition in a space currently dominated by global pharma giants. While the Canadian approval is a significant milestone, broader expansion—especially into markets like the United States—may still face patent-related hurdles.

Industry watchers see this as an early signal of pricing pressure in the GLP-1 drug category. As more generic players enter, treatment costs could gradually decline, reshaping the competitive landscape while expanding patient access to these in-demand therapies.